Correction to: Neuropsychopharmacology (2010) 35, 2367–2377; doi:10.1038/npp.2010.111; published online 4 August 2010
In this article, the authors would like to apologize for an error inadvertently introduced into the paper. During pre-marketing clinical studies, reactions that presented with signs and symptoms consistent with olanzapine overdose were reported in patients following an injection of olanzapine pamoate. These reactions occurred in <0.1% of the injections and in approximately 2% of patients, according to the EU SPC, for olanzapine pamoate.1,2 In the EU SPC, at the moment the manuscript was written, post-injection delirium syndrome (PDSS) occurred in approximately 1% of patients. In the introduction section on page 2, we inadvertently stated that PDSS occurred after about 1% of olanzapine pamoate injections (Citrome, 2009). The authors intended to state that PDSS occurs in about 1% of patients receiving olanzapine pamoate injections. We now have updated the note according to the EU SPC, stating that PDSS occurs in <0.1% of olanzapine pamoate injections and in about 2% of patients.
Citrome L (2009). Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 63: 140–150.
Additional information
The online version of the original article can be found at 10.1038/npp.2010.111
Rights and permissions
About this article
Cite this article
Gaebel, W., Schreiner, A., Bergmans, P. et al. Erratum: Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial. Neuropsychopharmacol 36, 548 (2011). https://doi.org/10.1038/npp.2010.206
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2010.206
